Law360, New York (November 04, 2005) -- In the most recent development in a court battle that is poised to enter its fourth year, a district court judge denied both the Mylan’s and Pfizer’s requests for summary judgment, sending the drug companies back to court over the patents for $2.5 billion drug Norvasc.
A judge in the U.S. District Court for the Western District of Pennsylvania denied Mylan’s motion for summary judgment seeking the invalidity of one of Pfizer’s patents for the hypertension...
